Why this is still worth your time: an oscilloscope is one of those tools where small misunderstandings compound into bad ...

Shares of digital analytics platform Amplitude (NASDAQ:AMPL) jumped 5.9% in the afternoon session after the investment firm BTIG initiated coverage on the stock with a "Buy" rating and a $14 price ...

Amplitude didn’t mean to start a fight when it launched its new AI Visibility tool in November - but it accidentally kicked a hornet’s nest anyway. The premise was simple enough: a free tool that ...

The presentation will be webcast live on the investor relations section of Amplitude’s website at investors.amplitude.com. A replay of the presentation will be available on the same website following ...

“But the Queen has no such veto. She must sign her own death-warrant if the two Houses unanimously send it up to her. It is a fiction of the past to ascribe to her legislative power (The English ...

Amplitude offers a compelling value opportunity with bargain-basement multiples and a turnaround in fundamentals not yet fully appreciated by the market. AMPL's Q3 beat-and-raise quarter, accelerating ...

Amplitude's comeback may have just begun. Three years after OpenAI launched ChatGPT, sparking a surge in semiconductor stocks like Nvidia, software stocks now seem to reap the benefits. After all, ...

SAN FRANCISCO--(BUSINESS WIRE)-- Amplitude, Inc. (Nasdaq: AMPL), the leading digital analytics platform, today announced the launch of AI Visibility, a new capability that gives marketers ...

Amplitude is undervalued, trading at less than 4x forward revenue, despite a strong recurring revenue base and improving retention rates. Q2 results showed accelerating revenue growth, a ...

Amplitude delivered better-than-expected results in its Q2 report. The response to its AI agents has been strong so far. Forrester ranked the company as a leader in digital analytics. The big news for ...

AI Agents work 24/7 to analyze user behavior, run experiments, and optimize product experiences so teams can achieve more Resource constraints are a universal pain point for product, marketing, and ...

ENLIGHTED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC). This ...